Search

Fellowships & Grants Committee

Current committee members
Dominique Bonnet, United Kingdom (Chair (EHA Board))
David Kent, United Kingdom (Vice-Chair (non-Board))
Regular members
Renée Beekman, Spain
Olivier Bernard, France
Niccolò Bolli, Italy
Tom Cupedo, The Netherlands
Michaela Fontenay, France
Julia Hauer, Germany
Antonis Kattamis, Greece
Elisa Laurenti, United Kingdom
Dimitrios Mougiakakos, Germany
César Nombela-Arrieta, Switzerland
Rebekka Schneider-Kramann, The Netherlands
Jürg…

Challenges and opportunities in the diagnostics and management of onco-hematological patients under the microscope during tutorial in Russia

May 12 2019 Posted in Meeting reports, Tutorial reports

Onco-hematology was the focus of the two-day EHA Hematology Tutorial in Moscow, Russia, the third joint tutorial organized by EHA, the National Hematological Society (NHS) and the Russian-Oncohematology Society (ROHS).

EHA Kick-off Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Epidemiology of infection in AML: A European Hematology Association survey (EPIAMLINF)

Project team

Jon Salmanton-García
Institution: University of Cologne, Germany

Biography: My research focuses on infectious diseases in hematology, particularly fungal infections and viral complications in immunocompromised patients.

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Jun 13 2014 Posted in Press releases

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Highlights from the SWG

Most impactful activitiesHIV Registry (NCT05231135)This unique retrospective and prospective EHA LyG European registry was initiated in August 2021, but recruitment was stalled due to objections from the local Ethics Committee.

Does the patient with myelofibrosis feel better through Pacritinib?

Jun 12 2015 Posted in Press releases

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.